CompletedNot applicableNCT00899496

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.

Checked against the public recordLast updated May 30, 2017 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorWake Forest University Health Sciences
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Other: immunological diagnostic method; Other: physiologic testing
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: -Meets 1 of the following criteria: * Diagnosis of metastatic cancer including, but not limited to, any of the following: * Stage IV non-small cell lung cancer * Extensive-stage small cell lung cancer * Metastatic testicular cancer * Stage IV breast carcinoma * Stage III or IV ovarian carcinoma * Stage IV endometrial carcinoma * Stage IV prostate carcinoma * Stage IV colorectal or pancreatic cancer * Stage IV renal cancer * Stage III or IV non-Hodgkin's lymphoma * Stage IV bladder cancer * Stage III multiple myeloma (Salmon-Durie staging) * Metastatic melanoma * Metastatic sarcoma * Healthy participant, meeting the following criteria: * No prior cancer * Over 50 years of age Exclusion Criteria: * Serious medical or psychiatric condition that would preclude study compliance * Chemotherapy or radiotherapy within the past 3 months (patient) * Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Wake Forest University Comprehensive Cancer CenterWinston-Salem, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 30, 2017. Always confirm current availability with the study team.

View original record ↗